BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38216927)

  • 1. Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.
    Yuan H; Mao X; Yan Y; Huang R; Zhang Q; Zeng Y; Bao M; Dai Y; Fang B; Mi J; Xie Y; Wang X; Zhang H; Mo Z; Yang R
    J Transl Med; 2024 Jan; 22(1):48. PubMed ID: 38216927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder.
    Ma G; Jia H; Zhang G; Liang Y; Dong X; Fu G; Wang X; Niu H
    Oncologist; 2024 Feb; 29(2):e248-e258. PubMed ID: 37874923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
    Front Immunol; 2021; 12():793992. PubMed ID: 35145509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
    Benítez R; Yu K; Sirota M; Malats N; Pineda S
    Front Immunol; 2023; 14():986598. PubMed ID: 36817478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
    Zhou L; Xu B; Liu Y; Wang Z
    Oncoimmunology; 2021 May; 10(1):1915574. PubMed ID: 34104539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1
    Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.
    Sakimura C; Tanaka H; Okuno T; Hiramatsu S; Muguruma K; Hirakawa K; Wanibuchi H; Ohira M
    J Surg Res; 2017 Jul; 215():74-82. PubMed ID: 28688665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
    An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
    Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
    Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
    Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer.
    Qin M; Hamanishi J; Ukita M; Yamanoi K; Takamatsu S; Abiko K; Murakami R; Miyamoto T; Suzuki H; Ueda A; Hosoe Y; Horie A; Yamaguchi K; Mandai M
    Cancer Immunol Immunother; 2022 Jun; 71(6):1431-1442. PubMed ID: 34689225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.
    Yamakoshi Y; Tanaka H; Sakimura C; Deguchi S; Mori T; Tamura T; Toyokawa T; Muguruma K; Hirakawa K; Ohira M
    Int J Oncol; 2020 Jul; 57(1):171-182. PubMed ID: 32319601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
    Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
    Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
    Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
    J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer.
    Xia J; Xie Z; Niu G; Lu Z; Wang Z; Xing Y; Ren J; Hu Z; Hong R; Cao Z; Han S; Chu Y; Liu R; Ke C
    Immunology; 2023 Jan; 168(1):135-151. PubMed ID: 36082430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
    Kinker GS; Vitiello GAF; Diniz AB; Cabral-Piccin MP; Pereira PHB; Carvalho MLR; Ferreira WAS; Chaves AS; Rondinelli A; Gusmão AF; Defelicibus A; Dos Santos GO; Nunes WA; Claro LCL; Bernardo TM; Nishio RT; Pacheco AM; Laus AC; Arantes LMRB; Fleck JL; de Jesus VHF; de Moricz A; Weinlich R; Coimbra FJF; de Lima VCC; Medina TDS
    Gut; 2023 Oct; 72(10):1927-1941. PubMed ID: 37230755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
    Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.